Cargando…

Immune checkpoint inhibitor-related acral vasculitis

Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma. We report a similar case of acral vasculitis occurring with a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comont, Thibault, Sibaud, Vincent, Mourey, Loïc, Cougoul, Pierre, Beyne-Rauzy, Odile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240222/ https://www.ncbi.nlm.nih.gov/pubmed/30446009 http://dx.doi.org/10.1186/s40425-018-0443-6

Ejemplares similares

Nivolumab-induced eosinophilic fasciitis: a case report
por: Ollier, Natasha, et al.
Publicado: (2020)

Severe aphthous stomatitis secondary to vitamin B12 deficiency with isotretinoin therapy
por: Vigarios, Emmanuelle, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Polymorphous acral eruption and Covid-19
por: Elkhachine, Youness, et al.
Publicado: (2020)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
por: Oishi, Hideo, et al.
Publicado: (2020)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Acral Melanoma: A Patient’s Experience and Physician’s Commentary
por: Greenwald, Elizabeth, et al.
Publicado: (2018)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study
por: Moulis, Guillaume, et al.
Publicado: (2021)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Does acral melanoma need a distinctive prognostic staging system?
por: Carrera, Cristina, et al.
Publicado: (2022)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
por: Gambichler, Thilo, et al.
Publicado: (2017)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021)

Checkpoint inhibitor–associated cutaneous small vessel vasculitis
por: Castillo, Brianna, et al.
Publicado: (2018)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
por: Neilan, Tomas G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_golaa221snebugmo7p2uab3j0p